ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378
Ru
En

Clinical Metabolic Disorders in Primary Hyperparathyroidism

DOI:10.31550/1727-2378-2020-19-2-51-55
Bibliography link: Torosyan M.R., Kiseleva T.P., Chzhen T.R. Clinical Metabolic Disorders in Primary Hyperparathyroidism. Doctor.Ru. 2020; 19(2): 51–55. (in Russian) DOI: 10.31550/1727-2378-2020-19-2-51-55
Clinical Metabolic Disorders in Primary Hyperparathyroidism
22 April 10:06

Objective of the Review: to briefly present characteristics of clinical metabolic disorders in primary hyperparathyroidism (PHPT) taking into account recent data.

Key Points. PHPT, a most common cause of hypercalcemia, affects predominantly postmenopausal women. Over the previous 40 years, clinical features have been reviewed. The disease comprises three differing clinical phenotypes, and each of them has been thoroughly studied; as a result, new concepts emerged that relate to target organ damage and patient management. It is now accepted that PHPT comprises three clinical phenotypes: marked target organ damage, mild asymptomatic hypercalcemia, and a phenotype with high serum parathormone concentration with stable normal albumin-adjusted and ionised calcium.

Conclusion. More and more information on PHPT signs and target organ damage is appearing; new patient management methods have been developed. New visualisation methods allowed identifying conditions which previously were diagnosed accidentally during biochemical testing. Awareness of possible signs of the disease is vital both for differential diagnosis and forecasting development of PHPT-associated pathologies.

Contribution: Torosyan, M.R., Chzhen, T.R. — thematic publications reviewing, manuscript preparation; Kiseleva, T.P. — review of critically important material, approval of the manuscript for publication.

Conflict of interest: The authors declare that they do not have any conflict of interests.

M.R. Torosyan (Corresponding author) — Ural State Medical University of the Ministry of Health of the Russian Federation; 3 Repin Str., Ekaterinburg, Russian Federation 620028. eLIBRARY.RU SPIN: 1710-0820. E-mail: ri-to4ka@bk.ru

T.P. Kiseleva — Ural State Medical University of the Ministry of Health of the Russian Federation; 3 Repin Str., Ekaterinburg, Russian Federation 620028. eLIBRARY.RU SPIN: 3072-5384. Е-mail: kistapet@mail.ru

T.R. Chzhen — Ural State Medical University of the Ministry of Health of the Russian Federation; 3 Repin Str., Ekaterinburg, Russian Federation 620028. eLIBRARY.RU SPIN: 2299-4784. E-mail: doctortrtr@mail.ru

Table
Main signs of symptomatic primary hyperparathyroidism

t8_1.jpg

Received: 03.03.2020
Accepted: 16.03.2020

Clinical Metabolic Disorders in Primary Hyperparathyroidism
22 April 10:06
LITERATURE
  1. Albright F. A page out of the history of hyperparathyroidism. J. Clin. Endocrinol. Metab. 1948; 8(8): 637–57. DOI: 10.1210/jcem-8-8-637
  2. NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann. Intern. Med. 1991; 114(7): 593–7. DOI: 10.7326/0003-4819-114-7-593
  3. Bilezikian J.P., Potts J.T. Jr, Fuleihan Gel.-H., Kleerekoper M., Neer R., Peacock M. et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J. Bone Miner. Res. 2002; 17(suppl2): N2–11.
  4. Bilezikian J.P., Khan A.A., Potts J.T. Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 2009; 94(2): 335–9. DOI: 10.1210/jc.2008-1763
  5. Bilezikian J.P., Brandi M.L., Eastell R., Silverberg S.J., Udelsman R., Marcocci C. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 2014; 99(10): 3561–9. DOI: 10.1210/jc.2014-1413
  6. Albright F., Aub J.C., Bauer W. Hyperparathyroidism: common and polymorphic condition as illustrated by seventeen proven cases in one clinic. JAMA. 1934; 102(16): 1276–87. DOI: 10.1001/jama.1934.02750160010003
  7. Revollo L., Civitelli R. Molecular actions of parathyroid hormone. In: Bilezikian J.P., ed. The parathyroids. San Diego: Elsevier; 2015: 119–26.
  8. Silva B., Kousteni S. Cellular actions of PTH: osteoblasts, osteoclasts, and osteocytes. In: Bilezikian J.P., ed. The parathyroids. San Diego: Elsevier; 2015: 127–38.
  9. Brandi M.L., Bilezikian J.P., Shoback D., Bouillon R., Clarke B.L., Thakker R.V. et al. Management of hypoparathyroidism: summary statement and guidelines. J. Clin. Endocrinol. Metab. 2016; 101(6): 2273–83. DOI: 10.1210/jc.2015-3907
  10. Bilezikian J.P., Bandeira L., Khan A., Cusano N.E. Hyperparathy­roidism. Lancet. 2018; 391(10116): 168–78. DOI: 10.1016/S0140-6736(17)31430-7
  11. Bilezikian J.P., Cusano N.E., Khan A.A., Liu J.M., Marcocci C., Bandeira F. Primary hyperparathyroidism. Nat. Rev. Dis. Primers. 2016; 2: 16033. DOI: 10.1038/nrdp.2016.33
  12. Bilezikian J.P. Primary hyperparathyroidism. In: DeGroot L., ed. www.ENDOTEXT.org (version of 2019); Singer F., Section Editor. South Dartmouth, MA: MDTEXT.COM Inc.; 2019.
  13. Piketty M.L., Prie D., Sedel F., Bernard D., Hercend C., Chanson P. et al. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin. Chem. Lab. Med. 2017; 55(6): 817–25. DOI: 10.1515/cclm-2016-1183
  14. Griebeler M.L., Kearns A.E., Ryu E., Thapa P., Hathcock M.A., Melton L.J. III et al. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J. Clin. Endocrinol. Metab. 2016; 101(3): 1166–73. DOI: 10.1210/jc.2015-3964
  15. Szalat A., Mazeh H., Freund H.R. Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur. J. Endocrinol. 2009; 160(2): 317–23. DOI: 10.1530/EJE-08-0620
  16. Marx S.J. Familial hypocalciuric hypercalcemia as an atypical form of primary hyperparathyroidism. J. Bone Miner. Res. 2018; 33(1): 27–31. DOI: 10.1002/jbmr.3339
  17. Dedov I.I., Mel'nichenko G.A., Pronin B.C., Romantsova T.I., Fadeev V.V., Gurova O.Yu. et al. Clinic and diagnosis of endocrine disorders. M.; 2005: 99–111. (in Russian)
  18. Silverberg S.J., Bilezikian J.P. “Incipient” primary hyperpara­thyroidism: a “forme fruste” of an old disease. J. Clin. Endocrinol. Metab. 2003; 88(11): 5348–52. DOI: 10.1210/jc.2003-031014
  19. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., Shaw A.C., Deraska D.J., Kitch B.T. et al. Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 1998; 338(12): 778–83. DOI: 10.1056/NEJM199803193381201
  20. Bendz H., Sjödin I., Toss G., Berglund K. Hyperparathyroidism and long-term lithium therapy — a cross-sectional study and the effect of lithium withdrawal. J. Intern. Med. 1996; 240(6): 357–65. DOI: 10.1046/j.1365-2796.1996.28864000.x
  21. Lavryk O.A., Siperstein A.E. Use of calcium and parathyroid hormone nomogram to distinguish between atypical primary hyperparathyroidism and normal patients. World J. Surg. 2017; 41(1): 122–8. DOI: 10.1007/s00268-016-3716-6
  22. Rosário P.W. Primary hyperparathyroidism with normal calcium and PTH. World J. Surg. 2017; 41(6): 1649–50. DOI: 10.1007/s00268-017-3888-8
  23. Tuna M.M., Çalışkan M., Ünal M., Demirci T., Doğan B.A., Küçükler K. et al. Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J. Bone Miner. Metab. 2016; 34(3): 331–5. DOI: 10.1007/s00774-015-0673-3
  24. Silverberg S.J., Clarke B.L., Peacock M., Bandeira F., Boutroy S., Cusano N.E. et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 2014; 99(10): 3580–94. DOI: 10.1210/jc.2014-1415
  25. Cipriani C., Biamonte F., Costa A.G., Zhang C., Biondi P., Diacinti D. et al. Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J. Clin. Endocrinol. Metab. 2015; 100(4): 1309–15. DOI: 10.1210/jc.2014-3708
  26. Tay Y.D., Liu M., Bandeira L., Bucovsky M., Lee J.A., Silverberg S.J. et al. Occult urolithiasis in asymptomatic primary hyperparathyroidism. Endocr. Res. 2018; 43(2): 106–15. DOI: 10.1080/07435800.2018.1431275
  27. Bandeira F., Cusano N.E., Silva B.C., Cassibba S., Almeida C.B., Machado V.C. et al. Bone disease in primary hyperparathyroidism. Arq. Bras. Endocrinol. Metabol. 2014; 58(5): 553–61. DOI: 10.1590/0004-2730000003381
  28. Misiorowski W., Czajka-Oraniec I., Kochman M., Zgliczyński W., Bilezikian J.P. Osteitis fibrosa cystica — a forgotten radiological feature of primary hyperparathyroidism. Endocrine. 2017; 58(2): 380–5. DOI: 10.1007/s12020-017-1414-2
  29. Bilezikian J.P., Silverberg S.J., Gartenberg F., Kim T.S., Jacobs T., Siris E. et al. Clinical presentation of primary hyperparathyroidism. In: Bilezikian J.P., Marcus R, Levine M.A., eds. The parathyroids. New York: Raven Press; 1994: 457–70.
  30. Walker M.D., Silverberg S.J. Non-traditional manifestations of primary hyperparathyroidism. In: Bilezikian J.P., ed. The parathyroids. San Diego, CA: Elsevier; 2015: 469–80.
  31. Cusano N.E., Maalouf N.M., Wang P.Y., Zhang C., Cremers S.C., Haney E.M. et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J. Clin. Endocrinol. Metab. 2013; 98(7): 2734–41. DOI: 10.1210/jc.2013-1300
  32. Bollerslev J., Jansson S., Mollerup C.L., Nordenström J., Lundgren E., Tørring O. et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J. Clin. Endocrinol. Metab. 2007; 92(5): 1687–92. DOI: 10.1210/jc.2006-1836
  33. Ambrogini E., Cetani F., Cianferotti L., Vignali E., Banti C., Viccica G. et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J. Clin. Endocrinol. Metab. 2007; 92(8): 3114–21. DOI: 10.1210/jc.2007-0219
  34. Walker M.D., McMahon D.J., Inabnet W.B., Lazar R.M., Brown I., Vardy S. et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J. Clin. Endocrinol. Metab. 2009; 94(6): 1951–8. DOI: 10.1210/jc.2008-2574
  35. Albright F., Reifenstein E.C. Jr. Parathyroid glands and metabolic bone disease. Baltimore, MD: Williams and Wilkins; 1948: 46–114.
  36. Patten B.M., Bilezikian J.P., Mallette L.E., Prince A., Engel W.K., Aurbach G.D. Neuromuscular disease in primary hyperparathyroidism. Ann. Intern. Med. 1974; 80(2): 182–93. DOI: 10.7326/0003-4819-80-2-182
  37. Rihsieva N.T. Primary hyperparathyroidism: etiology, pathogenesis, clinical features, diagnosis, treatment, quality of life (literature review). International Endocrinological Journal. 2014; 1(57): 103–7. (in Russian)
  38. Voronenko I.V., Mokrysheva N.G., Rozhinskaya L.Yа., Syrkin A.L. Disorders of carbohydrate and fat metabolism in primary hyperparathyroidism. Obesity and Metabolism. 2008; 4: 18–24. (in Russian)
  39. Turken S.A., Cafferty M., Silverberg S.J., De La Cruz L., Cimino C., Lange D.J. et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am. J. Med. 1989; 87(5): 553–7. DOI: 10.1016/s0002-9343(89)80613-8
  40. Lowe H., McMahon D.J., Rubin M.R., Bilezikian J.P., Silver­berg S.J. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 2007; 92(8): 3001–5. DOI: 10.1210/jc.2006-2802
  41. Pawlowska M., Cusano N.E. An overview of normocalcemic primary hyperparathyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 2015; 22(6): 413–21. DOI: 10.1097/MED.0000000000000198
  42. Maruani G., Hertig A., Paillard M., Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized targettissue resistance to parathyroid hormone. J. Clin. Endocrinol. Metab. 2003; 88(10): 4641–8. DOI: 10.1210/jc.2002-021404
  43. Tordjman K.M., Greenman Y., Osher E., Shenkerman G., Stern N. Charac­terization of normocalcemic primary hyperparathyroidism. Am. J. Med. 2004; 117(11): 861–3. DOI: 10.1016/j.amjmed.2004.06.037
  44. Amaral L.M., Queiroz D.C., Marques T.F., Mendes M., Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J. Osteoporos. 2012; 2012: 128352. DOI: 10.1155/2012/128352
  45. Castellano E., Attanasio R., Gianotti L., Cesario F., Tassone F., Borretta G. Forearm DXA increases the rate of patients with asymptomatic primary hyperparathyroidism meeting surgical criteria. J. Clin. Endocrinol. Metab. 2016; 101(7): 2728–32. DOI: 10.1210/jc.2016-1513
Similar article
19 May 15:04, Allergology
V.M. Ganuzin, N.L. Chernaya, G.S. Maskova
Features of Specialised Medical Consultation of Adolescents with Bronchial Asthma: Clinical Observation
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)
19 May 14:30, Allergology
S.E. Mitskevich, I.A. Fedorov, A.I. Chuprynina, O.G. Rybakova
Use of Omalizumab in Management of Severe Uncontrolled Bronchial Asthma in Children
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)

Partners